Albany, NY, November 13, 2016 --(PR.com
)-- Market Research Hub (MRH) has broadcasted the addition of a new forecast report, titled “PharmaPoint: Venous Thromboembolism- Global Drug Forecast and Market Analysis to 2025” to its expanding database. The report forecasts the Venous Thromboembolism market containing deep vein thrombosis and pulmonary embolism, to grow at a compound annual growth rate (CAGR) of 2.89% across the seven chief markets of US, France, Germany, Italy, Spain, the UK and Japan.
Request a Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=855951
The report begins with the overview of venous thromboembolism (VTE) along with its symptoms, etiology and prognosis. It is a disease which includes many life-threatening disorders ranging from pulmonary embolism to deep vein thrombosis. Basically, VTE is the evolution of blood clots in the vein. When a blood clot forms in a deep vein, usually in the leg, it is called a deep vein thrombosis or DVT and if that clot breaks loose and travels to the lungs, it is tagged as pulmonary embolism (PE).
VTE has now became very much common in adults and in older people, but it can occur at any age. Young patients with this disease usually have strong influencing factors, such as multiple trauma, leg fractures or indwelling central vein lines. But in children, it is a rare phenomenon. According to the analysis, it is observed that, there are about 2 million people in the United States who suffer from deep vein thrombosis every year.
Browse More Info with TOC: http://www.marketresearchhub.com/report/pharmapoint-venous-thromboembolism-global-drug-forecast-and-market-analysis-to-2025-report.html
Additionally, the report provides epidemiological forecast for VTE during the period of 2015 to 2025. It includes the key insights with the limitations and lucid analysis of the global market. Further, it highlights the Novel oral anticoagulants (NOACs) that will be the key driving force behind the anticipated growth in the VTE market. NOACs such as Pradaxa, Eliquis, Xarelto and Savaysa provide physicians with numerous treatment options, which can be managed depending upon the patient’s risk profile. All of these drugs are currently available and will show enhanced approval over the forecast period. In the report, one can also gain knowledge about the drugs that will have the maximum sales at a higher CAGR.
In the report, pipeline analysis are also discussed which are obtained from the comprehensive data split across different phases, evolving novel trends under development and detailed assessment of late-stage drugs. The report will enable the buyer to understand the key trends, innovative products, companies marketing strategies and to create effective counter-strategies to gain a competitive advantage for their businesses.
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
90 State Street
Albany, NY 12207,
Toll Free : 866-997-4948 (US-Canada)
Tel : +1-518-621-2074
Email : firstname.lastname@example.org
Website : http://www.marketresearchhub.com/